REVIEW Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects. It is highly effective and well tolerated, and clinical trials as early as 1981. In 2003, the drug was withdrawn after reports of serious hepatotoxicity, although it is still marketed in several countries by other drug companies.
REFERENCES
[1]
Heel, R. C.; Brogden, R. N.; Speight, T. M.; Avery, G. S. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricemia. Drugs. (1977) 14(5): 349-66.
[2]
Lee, Ming-Han H.; Graham, Garry G.; Williams, Kenneth M.; Day, Richard O. A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients? Drug Safety. (2008) 31(8): 643-665.
[3]
Perez-Ruiz, Fernando; Hernando, Inaki; Herrero-Beites, Ana M. Uricosuric therapy Edited by Wortmann, Robert L. Crystal-Induced Arthropathies. (2006): 369-380.
[4]
Buu-Hoi, Nguyen Ph.; Beaudet, Camille Benzofurans (1961), US 3012042 19611205.
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
